Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus

Gilbert, Brian W.; Sherard, Max K.; Little, Lindsey; Branstetter, Joshua; Meister, Amber; Huffman, Joel B.

doi:10.1016/j.amjcard.2017.11.021

Cited by 14 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ranolazine also has metabolic effects, and may lower HbA1c levels in patients with DM. 329 Trimetazidine is an anti-ischaemic metabolic modulator that improves glucose control and cardiac function in patients with DM, 330,331 as well as effort-induced myocardial ischaemia in patients with CCS. 332 Recommendations on glucose targets are outlined in section 6.2.1.…”

Section: Other Anti-ischaemic Drugsmentioning

confidence: 99%

The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Grant

Cosentino

2019

European Heart Journal

384

331

View full text Add to dashboard Cite

show abstract

Section: Other Anti-ischaemic Drugsmentioning

confidence: 99%

The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Grant

Cosentino

2019

European Heart Journal

384

331

View full text Add to dashboard Cite

show abstract

“…The antianginal effects of ranolazine are achieved by blocking the late sodium channels, thereby preventing a downstream rise in cytosolic Ca 2+ concentrations . In addition, ranolazine may be useful in the management of stable ischaemic heart disease with diabetes, as indicated by a fall in circulating haemoglobin A1c …”

Section: Lifestyle and Pharmacological Interventions To Target Mitochmentioning

confidence: 99%

“…285 In addition, ranolazine may be useful in the management of stable ischaemic heart disease with diabetes, as indicated by a fall in circulating haemoglobin A1c. 286,287…”

Section: Compounds To Reduce Lipotoxicitymentioning

confidence: 99%

Altered mitochondrial metabolism in the insulin‐resistant heart

et al. 2019

View full text Add to dashboard Cite

Obesity‐induced insulin resistance and type 2 diabetes mellitus can ultimately result in various complications, including diabetic cardiomyopathy. In this case, cardiac dysfunction is characterized by metabolic disturbances such as impaired glucose oxidation and an increased reliance on fatty acid (FA) oxidation. Mitochondrial dysfunction has often been associated with the altered metabolic function in the diabetic heart, and may result from FA‐induced lipotoxicity and uncoupling of oxidative phosphorylation. In this review, we address the metabolic changes in the diabetic heart, focusing on the loss of metabolic flexibility and cardiac mitochondrial function. We consider the alterations observed in mitochondrial substrate utilization, bioenergetics and dynamics, and highlight new areas of research which may improve our understanding of the cause and effect of cardiac mitochondrial dysfunction in diabetes. Finally, we explore how lifestyle (nutrition and exercise) and pharmacological interventions can prevent and treat metabolic and mitochondrial dysfunction in diabetes.

show abstract

“…11 For example, it lowers hemoglobin A1c (HbA1c) and has positive antihyperglycemic and metabolic effects in patients with CAD and type 2 diabetes mellitus. 12,13 Ranolazine reduces oxidation of fatty acids and switches the energy source from fatty acids to glucose. 14,15 It increases hepatic pyruvate dehydrogenase (PDH) activity, the rate-limiting enzyme of glucose oxidation.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of the Impact of Ranolazine Treatment on Liver Function Tests in Patients With Coronary Heart Disease and Nonalcoholic Fatty Liver Disease

et al. 2021

View full text Add to dashboard Cite

Nonalcoholic fatty liver disease (NAFLD) is the most common liver pathology in the developed world. Nonalcoholic fatty liver disease is associated with a higher risk of cardiovascular disease. We investigated the impact of ranolazine on liver tests in patients with NAFLD and coronary artery disease (CAD). Patients who had established CAD and NAFLD (as assessed by raised serum transaminase activity, sonographic criteria, and the absence of any other obvious liver disease) were allocated to “on ranolazine” (n = 40) or “not on ranolazine” (n = 35) groups. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured in all patients at baseline and at the end of the study. After 6 months of ranolazine treatment, both ALT and AST activities were significantly lower in patients in the “on ranolazine” group compared with “not on ranolazine” patients (change from baseline: ALT, −11.0 ± 1.7 IU/L, P < .001; AST, −5.2 ± 1.9 IU/L, P =.009). In conclusion, the present study showed that treatment with ranolazine for 6 months led to a significant reduction in the activities of both serum aminotransferases in patients with stable CAD and NAFLD.

show abstract

Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus

Cited by 14 publications

References 22 publications

The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Altered mitochondrial metabolism in the insulin‐resistant heart

Evaluation of the Impact of Ranolazine Treatment on Liver Function Tests in Patients With Coronary Heart Disease and Nonalcoholic Fatty Liver Disease

Contact Info

Product

Resources

About